FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO -- Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived…
Browsing Tag
FGFR
Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of its…
SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of…
Kinnate Biopharma Inc. to Present Updates from its Lead RAF and FGFR Inhibitor…
AACR Special Conference: Targeting RAS presentation will highlight findings from real-world clinico-genomic study collaboration with Tempus investigating prevalence of Class II and Class…
FDA Approved Fibroblast Growth Factor Receptor FGFR Inhibitor Anticancer Drug Market…
Delhi, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 Report Highlights: Global FGFR…
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR…
CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and…
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR…
CAMBRIDGE, Mass. and NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and…